Company profile for Vividion Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Vividion Therapeutics is transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. We are advancing a broad, diversified pipeline of selective small molecule therapeutics for multiple highly sought-after disease-modifying target proteins in oncology and immunology. We are focused on the discovery, development and consolidation of unpr...
Vividion Therapeutics is transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. We are advancing a broad, diversified pipeline of selective small molecule therapeutics for multiple highly sought-after disease-modifying target proteins in oncology and immunology. We are focused on the discovery, development and consolidation of unprecedented insights and approaches to create small molecule medicines against the most sought-after targets in oncology and immunology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
5820 Nancy Ridge Drive San Diego, CA 92121
Telephone
Telephone
858.345.4690
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/bayer-bails-vividion-tumor-drug-part-early-stage-cancer-clear-out

FIERCE BIOTECH
12 Nov 2025

https://www.businesswire.com/news/home/20251009963422/en/Vividion-Announces-Publication-in-Science-of-Preclinical-Data-on-Covalent-Inhibitors-of-RAS-PI3K-that-Block-Tumor-Growth

BUSINESSWIRE
09 Oct 2025

https://www.businesswire.com/news/home/20250813751175/en/Vividion-Therapeutics-Appoints-Sam-Whiting-M.D.-Ph.D.-as-Chief-Medical-Officer

BUSINESSWIRE
13 Aug 2025

https://www.businesswire.com/news/home/20250604147547/en/Vividion-Therapeutics-and-Bayer-Further-Strengthen-Oncology-Development-Pipeline-with-Clinical-Stage-WRN-Inhibitor

BUSINESSWIRE
04 Jun 2025

https://www.fiercebiotech.com/biotech/bayers-vividion-secures-rights-worlds-only-clinical-stage-wrn-inhibitor-partner-roche

FIERCE BIOTECH
04 Jun 2025

https://www.businesswire.com/news/home/20250403585991/en/Vividion-Therapeutics-Doses-First-Patient-in-Phase-I-Study-of-RAS-PI3K-Inhibitor-for-Treatment-of-Advanced-Solid-Tumors

BUSINESSWIRE
03 Apr 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty